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• In patients with refractory gas-exchange abnormalities, extracorporeal 
membrane oxygenation (ECMO) is considered  rescue therapy that aims to 
decrease ventilator induced lung injury and provide lung rest.  
  INTRODUCTION 
 
•   To compare the cohort of patients who received ECMO as rescue therapy 
compared to  other forms of rescue therapy  at our institution. 
                    AIM 
•  We conducted a retrospective study of patients diagnosed with ARDS 
(N=149) from October 2010 to September 2012 at Thomas Jefferson 
Hospital. 
  
•  All patients mechanically ventilated with on the ARDS protocol were 
identified. Severity of illness and lung injury were determined based on 
APACHE  II, PaO2 / FiO2 ratio, Oxygenation Index (OI) and Murray score. 
•  Subjects who required additional therapy became the cohort known as 
rescue therapy.  These patients required the use of- inhaled Epoprostenol, 
neuromuscular blocking agents and /or Airway pressure release ventilation 
(APRV)  to identified. 
 
                METHODS 
Parameters	  
No rescue 
therapy 	  
Non ECMO 
rescue modality	  
ECMO  rescue 
modality	   CESAR Trial 	  
                                                  Demographics 
Total patients  n=149 	   87 (59%)	   48 (32%)	   14 (9%)	   90 
Age (years)	   56 (30-86)	   53 (22-91) 47 (17-77)	   40 
                                                      Etiology 
Pneumonia  49% 50% 50% 62% 
Sepsis 34% 30% 21% 
                                                      Initial Oxygenation 
FiO2	   60 (30-100)	   70 (40-100)	   100 (70-100)	  
Murray Score	   2 (1-4)	   3 (1.75-4) 3.5 (2.5-4)	   3.5 
Oxygenation Index	   7 (2-23)	   15 (3- 41) 26 (11-59)	  
PaO2/FiO2 	   94 (60-490)	   116 (53-383) 75 (41-144)	   76 
                                                   Initial Lung Mechanics  
Static  compliance	   30 (17-230)	   26 (11-75) 24 (10-60)	   28 
MAP cmH2O	   9 (7-26)	   18.5 (13-30) 21 (26-70)	  
PEEP cmH2O	   8 (5-14)	   10 (5-20) 15 (5-20)	   14 
pH	   7.40  (7.2-7.5)	          7.34 (7.13-7.5) 7.30 (6.96-7.5)	   7.10 
pCO2  mmHg	   41 30-68)	   40 (26-76) 45 (41-144)	  
pO2    mmHg	   92 (61-194)	   81(48-383) 69 (25-116)	  
APACHE II Score 	   23 (7-42)	   24 (8-43) 29 (11-39)	   20 
Mortality rate	   39%	   77%	   50%	   37% 
                RESULTS 
 
• 149 patients were identified, 62 patients received rescue therapy and 14 
required ECMO. 
• Six of 14 patients received Veno-arterial ECMO and the remaining 8 received 
Veno-venous ECMO. 
• Patients with ARDS placed on ECMO had an absolute reduction in mortality 
of 27% when compared to patients who received other  rescue modalities (77% 
vs. 50%; p = 0.32). 
 
             CONCLUSION 
•  We believe that ECMO may be an important rescue modality in the right 
clinical setting in patients with severe ARDS. 
•  Treating physicians should consider ECMO as a treatment modality for 
severe ARDS patients. 
Data are  number (%) or  median (range) 
 
A-a gradient: alveolar arterial gradient; MAP: Mean airway pressure, Oxygenation Index =  
FiO2 x MAP/ PaO2 
	
         DISCUSSION 
•  Patients with  severe ARDS have a high mortality rate and often receive 
rescue therapy for gas exchange abnormalities. 
•  There is growing appreciation that ECMO therapy is a valuable rescue 
therapy but there is controversy about selection of the  right candidate. 
 
•  There was a trend towards improved survival in the ECMO group. 
•  Severe hypoxemia coupled with elevated PaCO2  and younger age 
appeared to be triggers for use of ECMO at our institution. 
 
•  These data provide support for using ECMO as rescue therapy in select 
populations. Hopefully future research will identify parameters to identify 
patients early who will benefit from ECMO therapy. 
 
•  Our outcomes are similar to Cesar  trial. 
Initial patient characteristics in different treatment groups  
Different rescue  modalities  used in Non ECMO rescue group  
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